We map evidence graded clinical journeys against public health signals to support you in proving value for maximizing market share against complex clinical pathways. SignalIQ maps where patients should be, using the clinical pathway they travel before reaching treatment.
Complementary to existing analytics
No IT setup, no data sharing required from you. We run the analysis and deliver the intelligence.
From literature to live dashboard, structured to deliver directional intelligence before launch, without IT dependency or software licences.
Peer-reviewed literature seeds an evidence-graded clinical indicator taxonomy specific to the disease and geography.
Government health statistics and claims data structured by geographic unit, region, state, or province.
Statistical correlations identify which signals predict treatment burden. Only significant indicators contribute to the score.
Standalone intelligence output: zero IT implementation, no data sharing required and immediate compatibility with existing territory planning.
The model draws on observable, publicly available data across the full patient pathway, from upstream disease burden through to system infrastructure readiness.
Prevalence proxies identifying at-risk patient pools before diagnosis, the leading indicator of latent demand.
Clinical presentations recorded separately: patients symptomatic but not yet confirmed for the target disease.
Current standard-of-care volumes confirming active, treatable disease. The primary conversion-ready signal.
Specialist density and co-visit patterns, representing the care pathway the patient must traverse to reach treatment.
Signals revealing where patients are lost between diagnosis, specialist referral, and treatment initiation.
Infrastructure signals: trial sites, infusion capacity, and diagnostic throughput, revealing structurally ready regions.
Every region emerges from the model with a tier classification and a recommended commercial response, ready to sit in your monthly review.
Active patients on current standard of care. Most direct conversion opportunity.
Burden likely present but not reaching management. Education or access gap to address.
Patients bypassing earlier intervention. Upstream prevention story strongest here.
Thin market. Resources better deployed elsewhere this cycle.
SignalIQ runs the full analysis on our side. The client receives the intelligence, not a system to operate. No IT infrastructure required, no data sharing required from you, no platform to deploy or maintain.
All analysis is built on publicly available government databases. No insurer data, no patient records, no privacy risk. Fully compliant.
Published medical journals. Used to map the patient journey and validate every indicator against peer-reviewed clinical evidence.
National drug dispensing and procedure data by territory. The primary source for treatment proxies and surgical signal.
Medical infrastructure data. Clinic and specialist density mapping across geographic units.
Disease prevalence by ICD-10 code. Upstream burden signal for the target condition.
Pharma master data. Brand and manufacturer mapping for treatment proxy validation.
Regulatory, safety, and package insert data plus clinical trials registry for competitive pipeline intelligence.
Engagements are structured to deliver a working prototype early, so you see the methodology applied to your market before committing to a full engagement.
All analysis is based on publicly available, non-sensitive government data. Outputs are directional intelligence tools, not absolute patient counts.
Every engagement starts with a scoped discovery workshop, so you define the correlations that matter to your commercial team before any data is run.